Indian J Pharm Close
 

Table 10: Question 3 (iii): What is the appropriate choice of therapy for HR +ve/Her2 −ve breast cancer in the presence of significant visceral disease in the second‑line metastatic setting

Table 10: Question 3 (iii): What is the appropriate choice of therapy for HR +ve/Her2 −ve breast cancer in the presence of significant visceral disease in the second‑line metastatic setting